Evidence map›Paper›PMID 34914064›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Preclinical Assessment of the Immunogenicity of Experimental Leishmania Vaccines.

Vivian Tamietti Martins, Amanda Sanchez Machado, Maria Victoria Humbert, Myron Christodoulides, Eduardo Antonio Ferraz Coelho

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Vivian Tamietti MartinsPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Amanda Sanchez MachadoPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Maria Victoria HumbertNeisseria Research Group, Molecular Microbiology, School of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, England, UK.
Myron ChristodoulidesNeisseria Research Group, Molecular Microbiology, School of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, England, UK. mc4@soton.ac.uk.
Eduardo Antonio Ferraz CoelhoPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Universidade Federal de Minas Gerais · BRSouthampton General Hospital · GB

Funding

Medical Research Council MR/R005850/1
6 · The paper itself

Abstract

Leishmaniases are neglected diseases caused by Leishmania parasites and affect millions of people worldwide. The induction of protective immunity against infection by some species of Leishmania has stimulated the development of vaccine candidates against the disease. In this chapter we describe protocols for immunizing mice with a recombinant chimera vaccine containing selected epitopes that specifically stimulate a Th1-type immune response. We describe protocols for challenging mice with live Leishmania parasite and for measuring parameters of the immune response to vaccination and parasite infection, including the production of cytokines, nitric oxide, and IgG antibodies, and the contribution of CD4+ and CD8+ T cells. We also provide protocols for isolating mouse organs for cell culture and for quantifying parasite loads in unvaccinated control animals and in vaccine-protected animals. These protocols can form the basis of immunological studies of candidate Leishmania vaccines in the mouse, as a step toward further vaccine development for human use.

Indexed as

LeishmaniaLeishmaniasisLeishmaniasis VaccinesAnimalsCD8-Positive T-LymphocytesCytokinesLeishmaniasis, VisceralMiceMice, Inbred BALB CProtozoan ProteinsVaccine DevelopmentVaccines, SyntheticCytokinesLeishmaniasis VaccinesProtozoan ProteinsVaccines, SyntheticCytokinesLeishmaniaMouse modelNitric oxideTh1 type immunityVaccines

Identifiers

PMID34914064
OpenAlexW4200067333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.